Institut Gustave Roussy (GR)

CONSORTIUM

GR is one of the largest Cancer Center in Europe. GR has appointed 2500 professionals who have a dedicated competence in health care, teaching and/or research in cancer encompassing 300 scientists, 210 physicians and 880 nurses and assistants. The early clinical trial multi-disciplinary tumor board encompasses all DITEP experts in medical oncology, radiotherapy, hematology, immunotherapy, as well as experts in biopathology and imaging.

Role in CCE_DART

The early clinical trial multi-disciplinary tumor board encompasses all DITEP experts in medical oncology, radiotherapy, hematology, immunotherapy, as well as experts in biopathology and imaging. This weekly committee is in charge of the validation of all patients’ referral to phase I programmes, and for the review of all on-going trials and medical decision regarding any complex situations of safety or experimental treatment decisions.

The molecular pluridisciplinary committee, dedicated to the weekly review of the molecular tumor profiles performed within our precision medicine programs aims at including each phase I-eligible patient in the most adapted clinical trial based on actionable molecular abnormalities.